<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01673659</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-12-008</org_study_id>
    <nct_id>NCT01673659</nct_id>
  </id_info>
  <brief_title>A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 Mcg/Actuation Compared With Nasonex® Nasal Spray 50 Mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to demonstrate bioequivalence (comparable safety and
      efficacy) of the Test product to the Reference in the treatment of subjects seasonal allergic
      rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline for mean reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>2 week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the mean Instantaneous Total Nasal Symptom Score (iTNSS)</measure>
    <time_frame>2 weeks treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1220</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone furoate 50 mcg/actuation Nasal Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasonex Nasal Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle of the test product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasonex Nasal Spray</intervention_name>
    <arm_group_label>Reference product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Complete the informed consent/assent process.

          2. Male or female between 12-65 years of age.

          3. Female subjects of child-bearing potential must not be pregnant or nursing, must have
             a negative urine pregnancy test and abstain from sexual intercourse or use a reliable
             method of contraception during the study.

          4. Subjects will be eligible to participate if: a) Their total rTNSS is at least 6; b)
             Reflective rating for &quot;nasal congestion/stuffy nose&quot; is a score of &gt;2 at Visit 1; c)
             Reflective score of &gt;2 for at least one (1) of the remaining three (3) allergic
             rhinitis symptoms.

          5. A history (2 or more seasons) of seasonal allergy to at least one allergen known to be
             present during the study season, confirmed by a skin prick test. (A documented
             positive skin test within the previous 12 months is acceptable.)

        Exclusion Criteria:

          1. Female who is pregnant or nursing, who is not using or does not agree to use an
             acceptable form of contraception during the study, or who intends to become pregnant
             during the study.

          2. Subject has a history of hypersensitivity or allergy to Mometasone, any other
             corticosteroids or any of the other study medication ingredients.

          3. Patients who suffer from chronic signs and symptoms of Perennial Allergic Rhinitis
             (PAR) should be excluded from the study, unless the Investigator assesses that the
             patient's current signs and symptoms are a clear exacerbation of Seasonal Allergic
             Rhinitis (SAR), rather than chronic PAR.

          4. A total score of less than 6 on the rTNSS or a score less than 2 for &quot;nasal
             congestion&quot; or a score less than 2 for all of the remaining 3 symptoms.

          5. Subject has any condition or abnormality of the upper airway (ex: nasal polyps,
             obstruction, recent nasal surgery, structural abnormality, rhinitis medicamentosa,
             etc.) that, in the opinion of the Investigator, could interfere with administration of
             the product, evaluation of the subject's condition, or other aspect of the trial.

          6. Subject has experienced any upper respiratory tract infection or has experienced a
             sinus infection within the 30 days, or has a history of recurrent sinus infections
             i.e. acute or significant chronic sinusitis, preceding Visit 1.

          7. Subject has a history of asthma requiring chronic treatment within two years of study
             start.

          8. Subject lacks history of seasonal allergy to at least one allergen known to be present
             during the study season for at least the two preceding seasons.

          9. Subject has a negative skin test for all appropriate allergens known to be present
             during the study season.

         10. Treatment for oral Candidiasis within 30 days of starting the study, or a current oral
             Candidiasis infection.

         11. The subject has had recent exposure (30 days) or is at risk of being exposed to
             chicken pox or measles.

         12. Patients with any untreated fungal, bacterial, systemic viral infections within the
             previous 30 days.

         13. Subject requires treatment with systemic corticosteroids for any condition, or has
             received systemic or nasal steroids within the 30 days preceding Visit 1. Hormone
             replacement therapy is allowed, on condition that the subject has been on a stable
             dosing regimen for at least 90 days and remains on the same dosing regimen during the
             study.

         14. Subject used systemic anti-inflammatory agents* including aspirin** and non-steroidal
             anti-inflammatory (NSAIDs) within 3 days prior to Visit 1. (*Subjects may use
             Acetaminophen for pain relief, as needed, throughout the study. **Use of low-dose
             aspirin for cardiac prophylaxis is allowed).

         15. Subject had immunotherapy (including desensitization therapy to perennial allergens or
             seasonal allergens not found in the current season) initiated or the subject's dosage
             or frequency of immunotherapy has been adjusted within the 30 days preceding Visit 1.

         16. Subject had desensitization therapy to the seasonal allergen that is causing their
             allergic rhinitis within the previous 6 months.

         17. Subject presented with conjunctivitis or any other eye signs/symptoms that are not
             related to the diagnosis of SAR.

         18. Subject has used a topical (&gt;1%) or ophthalmic steroid preparation within 14 days
             preceding Visit 1. (Topical steroid preparations used for dermatological indications
             are permitted in concentrations of ≤1%.)

         19. Use of intranasal or systemic first generation anti-histamines, leukotriene receptor
             antagonists (montelukast) or other nasal decongestants within 3 days of Visit 1.

         20. Use of intranasal cromolyn within 14 days of Visit 1.

         21. Use of intranasal or systemic second-generation antihistamines (e.g. fexofenadine,
             loratadine, desloratadine, cetirizine) within 10 days of Visit 1.

         22. Subject has received immune-system therapy with AIC (an investigational vaccine
             created using immunostimulatory sequences derived from DNA), SLIT, Oral peptide
             sequence at any time.

         23. Subject has clinically significant acute or chronic hepatic disease.

         24. Subject has a history of alcoholism, drug abuse, or problems which would likely make
             him/her unreliable for the study.

         25. Subject has any condition or uses any medication which, in the opinion of the
             Investigator, might interfere with the conduct or results of the study or place the
             prospective subject at increased risk.

         26. Subject has received tricyclic antidepressants within the 30 days preceding Visit 1.

         27. Subject has been treated for attention-deficit hyperactivity disorder with an unstable
             dose of a methylphenidate-containing products during the 30 days preceding Visit 1, or
             a dose adjustment is anticipated during the study.

         28. Subject or the subject's parent/legal guardian is unwilling to sign the informed
             consent form.

         29. Subject is concurrently participating in another investigational study or using any
             investigational drug (or biologic) or device within the 30 days prior to Visit 1.

         30. Subject plans or anticipates travel outside the allergen-rich area for more than one
             day during the Run-In phase (Visit 1-Visit 2), or for more than two consecutive and
             three total days during the Treatment Period (Visit 2-Visit 3). (Whenever possible,
             subjects should remain in the allergen-rich area for the 3 days preceding Visit 2 and
             Visit 3.)

         31. Subject has a history or presence of cataracts, ocular herpes, or glaucoma.

         32. Subject has a history of tuberculosis.

         33. Subject has previously enrolled in this study.

         34. Subject has used the Reference Product (Nasonex) within 3 months prior to Visit 1.

         35. History of unresponsiveness to Mometasone Nasal Spray.

         36. Members of the Investigational study staff, or family members of the Investigational
             study staff.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2012</study_first_posted>
  <disposition_first_submitted>September 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2013</disposition_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

